FY25 ANNUAL REPORT

$115.6M

IN REVENUE

A record-setting year for Duke inventions, with revenue shared across inventors, labs, departments, and schools.

See More Numbers

Duke’s 7th Drug on the Market

With the approval of vorasidenib, seven drugs with Duke IP are now improving lives around the world.

READ THE STORY

Duke Capital Partners: A Record Year

$22M invested across 23 financings and four liquidity events in FY25.

VIEW DCP NUMBERS

$898K invested through OTC’s translational fund

LEARN MORE ABOUT THE FUND

11 new start-ups launched with Duke IP

SEE OUR START-UPS

10 years, $105M, 60 start-ups – and counting

READ OUR STORY

November 11th, 2025
7th Annual Invented at Duke Celebration

Duke’s Office for Translation & Commercialization invites you to Invented at Duke 2025, the annual celebration and showcase of Duke inventors and inventions – this year, with Ken Gall, MEMS professor and serial entrepreneur as our featured speaker. It will be held 4:30-7PM at the Penn Pavilion on Duke campus.

This event will feature inventors with booths, resource tables, drinks and hors d’oeuvres, gifts for Duke inventors who register and attend, as well as brief remarks from President Price and OTC head Robin Rasor. We hope to see you there!

FREE RSVP

362

INVENTIONS DISCLOSED

The pipeline for commercialization begins here.

See More Numbers

53 new company connections

Learn how the Technology Marketing team set up a record number of calls with industry partners, amplifying Duke’s presence in the marketplace.

READ THE STORY

76 student associates

OTC is building the next generation of innovation leaders at Duke.

SEE THE BREAKDOWN

Start-up workshop returns

Duke New Ventures guides researchers through launching start-ups in FDA-regulated markets.

READ THE STORY

$450M+ raised by Duke start-ups

restor3d, dannce.ai, Tune Therapeutics, VQ Biomedical, and other Duke start-ups closed big rounds in a difficult market.

SEE THE HIGHLIGHTS